Cresilon, a New York-based biotechnology company providing a safe solution to stop bleeding, raised $25M in Series A-4 funding.
The round was led by Paulson Investment Company.
The company intends to use the funds to accelerate its global growth plan, increase production capacity at biomanufacturing facility inĀ Brooklyn, and expand upon the launch of VETIGEL. It will also support Cresilon’s entry into the human health market following its submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for the company’s proprietary hemostatic gel technology.
Led by CEO Joe Landolina, Cresilon is a biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing its proprietary gel technology. VETIGELĀ® is a hemostatic gel for the animal health market that instantly stops bleeding in a wide variety of applications including emergency care and surgical procedures.
FinSMEs
31/10/2022